Immune to Cancer: The CRI Blog
-
Recap of the Fourth Annual Immuno-Oncology 360° Conference
The Fourth Annual Immuno-Oncology 360° Conference focused on comprehensive strategies for advancing immunotherapy, and was held from February…
-
How Man’s Best Friend Could Help Us Cure Cancer
Cancer very is similar in dogs and humans, and scientists are now exploring how cures for one…
-
Immunotherapy is Here to Stay: Looking Back at this Year’s Breakthroughs
Important immunotherapy breakthroughs benefited patients immensely in 2017 and paved the way for even more advances in…
-
Recent FDA Announcements Herald Advances in Personalized Approaches Against Cancer
Two tumor-profiling tests recently authorized by the FDA enable doctors to tailor their treatments more effectively to…
-
CRI Researcher Highlights New Technique to Aid Immunotherapy
Dr. Mohammad Rashidian’s nanobodies could help improve doctors’ decisions regarding immunotherapy.
-
Checkpoint Immunotherapy Approved for Patients with Stomach, Gastroesophageal, and Liver Cancer
Previously treated patients with these cancer types can now receive anti-PD-1 immunotherapy; nivolumab for HCC and pembrolizumab…
-
CICON17 Day 3 Recap: Combinations, Checkpoint Immunotherapy Resistance, Immunomodulators, and Microbiota
Day 3 of the CICON17 focused on combination therapies, immunomodulators, overcoming immune suppression, and the role bacteria in…
-
CICON17 Day 2 Recap: Biomarkers, Novel Agents, and Adoptive Cell Therapies
Day 2 of CICON17 offered a focused exploration of the latest discoveries and data from scientific studies…
-
CICON17 Day 1 Recap: Neoantigens, Vaccines, and Overcoming Immunotherapy Resistance
Day 1 of CICON17 explored how to identify and target neoantigens with vaccines and other strategies to…